Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age

Trial Profile

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal meningitis
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 29 Sep 2017 Planned End Date changed from 11 Oct 2017 to 13 Oct 2017.
    • 29 Sep 2017 Planned primary completion date changed from 11 Oct 2017 to 13 Oct 2017.
    • 28 Jun 2017 Planned End Date changed from 1 May 2018 to 11 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top